SIETES :: 92347 citas

Resultados de la búsqueda por REVISIÓN REFINAR BÚSQUEDA

1.

Elia J. Celecoxib gets partial exoneration from FDA panels. Physician's First Watch 2018:5. [Ref.ID 102574]

2.

Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neurospychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf 2018;41:marzo. [Ref.ID 102559]

3.

Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018:6 de marzo. [Ref.ID 102555]

4.

Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]

5.

Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]

6.

Anónimo. Drugs and their names. Drug Ther Bull 2018;56:marzo. [Ref.ID 102507]

7.

Moore PA, Ziegler KM, Lipman RD, Aminoshariae A, Carrasco-Labra A, Mariotti A. Benefits and harms associated with analgesic medications used in the management of acute dental pain. The Journal of the American Dental Association 2018;149:abril. [Ref.ID 102481]

8.

Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]

9.

Pennell PB. Antiepileptic drugs in pregnancy — Quick decisions with long-term consequences. JAMA Neurology 2018:1. [Ref.ID 102464]

10.

Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]

11.

12.

Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]

13.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

14.

Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med 2017;377:1580-2. [Ref.ID 102100]

15.

Poewe W, Seppi K. Insulin signalling: new target for Parkinson's treatments?. Lancet 2017;390:1628-30. [Ref.ID 102093]

16.

Alshehri GH, Keers RN, Ashcroft DM. Frequency and nature of medication errors and adverse drug events in mental health hospitals: a systematic review. Drug Saf 2017;40:871-86. [Ref.ID 102076]

17.

McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]

18.

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

19.

Anónimo. Lénalidomide et lymphome du manteau en rechute ou réfractaire. Prescrire 2017;37:572-4. [Ref.ID 102041]

20.

Anónimo. Ivacaftor et mucoviscidose (suite). Prescrire 2017;37:566-8. [Ref.ID 102040]